Drug intelligence / Profile preview

AMS-2140

Development stage: Preclinical
Lead developer: AMS BioteQ
Modality: Small Molecules

Overview

AMS-2140 is a preclinical-stage small molecule antiviral candidate being developed by AMS BioteQ. It is designed to target viral non-structural proteins (NS1 through NS5), which are essential for viral replication and immune evasion. The drug is currently being investigated for the treatment of Dengue virus and H5N1 avian influenza. By targeting these conserved non-structural proteins, AMS-2140 aims to inhibit the viral life cycle across multiple stages.

Targets

Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on AMS-2140.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMS-2140.

Explore the full profile